Of these markers, IgA antibodies against viral capsid antigens (VCA-IgA) and nuclear antigen 1 (EBNA1-IgA) have been used in several NPC screening trials for the general population in southern China12–14. Here, CD79A is linked to nasopharyngeal carcinoma.